Introduction

Asthma is a chronic inflammatory disease of the airways associated with bronchoconstriction, airway edema, mucus hypersecretion, and reversible airflow obstruction. It affects individuals of all age groups and is commonly triggered by allergens, respiratory infections, pollutants, exercise, and environmental irritants. The pharmacological treatment of asthma aims to relieve bronchospasm, suppress airway inflammation, reduce allergic responses, and improve respiratory function [1-2]. Various classes of anti-asthmatic drugs, including corticosteroids, β₂-adrenergic bronchodilators, anticholinergic bronchodilators, antihistamines, and nasal decongestants, are widely used in clinical practice. Structure–Activity Relationship (SAR) studies play an important role in medicinal chemistry by correlating chemical structure with biological activity. SAR analysis helps in understanding how structural modifications influence receptor binding, selectivity, potency, onset of action, duration of effect, metabolic stability, lipophilicity, and adverse effects [3-5]. Modifications such as halogen substitution, esterification, aromatic ring substitution, quaternary ammonium formation, and lipophilic side-chain addition have significantly improved the efficacy and safety of modern anti-asthmatic drugs. Understanding the SAR of anti-asthmatic agents has contributed to the development of highly selective inhaled corticosteroids, long-acting β₂-agonists, selective anticholinergic bronchodilators, non-sedating antihistamines, and effective nasal decongestants with reduced systemic toxicity. These advancements have greatly improved asthma control, patient compliance, and therapeutic outcomes.

Structure–Activity Relationship (SAR) of Anti-Asthmatic Corticosteroids

Anti-asthmatic corticosteroids are synthetic glucocorticoids mainly used as inhaled or systemic anti-inflammatory agents in asthma management. These drugs possess a common cyclopentanoperhydrophenanthrene steroid nucleus (17-carbon tetracyclic ring system), which is essential for glucocorticoid activity. Corticosteroids act by binding to glucocorticoid receptors and suppressing the production of inflammatory mediators involved in asthma [6]. Structure–Activity Relationship (SAR) studies explain how structural modifications at specific carbon positions influence glucocorticoid potency, receptor affinity, lipophilicity, duration of action, topical selectivity, and systemic adverse effects. Changes such as halogen substitution, hydroxyl groups, double bonds, and esterification enhance anti-inflammatory activity and improve therapeutic efficacy while reducing toxicity. Understanding the SAR of corticosteroids has led to the development of effective inhaled corticosteroids with improved safety profiles for asthma management.

General SAR of Corticosteroids

1. The steroidal nucleus is essential for glucocorticoid activity.
2. A double bond between C1–C2 increases anti-inflammatory potency.
3. Hydroxyl groups at C11 and C17 are important for glucocorticoid receptor binding.
4. Substitutions at C6 and C16 modify glucocorticoid and mineralocorticoid activity.
5. C6 methyl substitution reduces mineralocorticoid activity while increasing potency.
6. Lipophilic ester groups prolong lung retention and reduce systemic bioavailability.
7. Increased lipophilicity enhances membrane penetration, topical activity, lung retention, and duration of action while reducing systemic absorption.
8. Halogen substitution, especially fluorine or chlorine, increases glucocorticoid potency and receptor affinity.
9. Halogen substitution improves anti-inflammatory action and receptor binding.
10. Acetonide and acetal groups enhance topical anti-inflammatory activity.
11. Some corticosteroids act as prodrugs and are converted into active metabolites in the lungs or liver.
12. Prodrug formation improves pulmonary selectivity and minimizes systemic adverse effects.

The therapeutic efficacy of anti-asthmatic corticosteroids is highly dependent on structural modifications of the steroid nucleus. Alterations such as fluorination, esterification, halogen substitution, and acetonide formation improve glucocorticoid potency, receptor affinity, pulmonary selectivity, and duration of action while minimizing systemic adverse effects. These SAR modifications have enabled the development of highly

2. Structure–Activity Relationship (SAR) of β₂-Adrenergic Bronchodilators

β₂-Adrenergic bronchodilators are sympathomimetic agents used in the treatment of asthma and other obstructive airway diseases. These drugs act by stimulating β₂-adrenergic receptors in bronchial smooth muscle, producing bronchodilation and relief of bronchospasm. Structurally, most β₂-agonists possess a phenyl ethanolamine nucleus containing an aromatic ring, ethanolamine side chain, and substituted amino group, which are essential for adrenergic activity [7]. Structure–Activity Relationship (SAR) studies explain how modifications in the aromatic ring, amino substituents, hydroxyl groups, and lipophilic side chains influence β₂ selectivity, potency, onset, duration of action, metabolic stability, and adverse effects. These structural modifications have led to the development of short-acting and long-acting β₂-adrenergic bronchodilators with improved therapeutic efficacy and safety in the management of asthma and chronic obstructive pulmonary disease (COPD).

General SAR of β₂-Adrenergic Bronchodilators

1. A two-carbon side chain between the aromatic ring and the amino group is essential for adrenergic activity.
2. Secondary amine structure is important for receptor interaction.
3. Aromatic rings such as phenyl, substituted phenyl, benzyl alcohol, phenoxy, phenol, or cyclohexyl groups influence activity and duration.
4. An aromatic ring with hydroxyl substitutions is necessary for β₂-adrenergic receptor activity.
5. Ethanolamine side chain is required for sympathomimetic and bronchodilator action.
6. Bulky substitution on the amino nitrogen increases β₂ selectivity and reduces β₁-mediated cardiac effects.
7. Increased lipophilicity prolongs the duration of bronchodilator action.
8. Long lipophilic side chains anchor the drug to the receptor membrane, producing prolonged activity.
9. Short lipophilic chains provide a rapid onset but shorter duration of action.
10. Hydroxyl substitutions improve bronchodilator activity and receptor affinity.
11. Resistance to catechol-O-methyltransferase (COMT) metabolism prolongs the duration of action.
12. Increased polarity decreases CNS penetration and reduces systemic adverse effects.

The SAR of β₂-adrenergic bronchodilators demonstrates that modifications in the aromatic ring, amino substituents, and lipophilic side chains strongly influence receptor selectivity, onset, and duration of action. Bulky N-substitutions enhance β₂ selectivity, while increased lipophilicity prolongs bronchodilator activity. These structural modifications have resulted in effective short-acting and long-acting bronchodilators with improved therapeutic efficacy and reduced adverse effects in asthma management.

3. Structure–Activity Relationship (SAR) of Anticholinergic Bronchodilators

Anticholinergic bronchodilators are muscarinic receptor antagonists used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) [8]. These drugs act by blocking muscarinic (M₃) receptors in bronchial smooth muscle, thereby inhibiting acetylcholine-mediated bronchoconstriction and producing bronchodilation. Structurally, most anticholinergic agents possess a quaternary ammonium group, an ester linkage, and bulky hydrophobic aromatic rings that are important for antimuscarinic activity. Structure–Activity Relationship (SAR) studies show that modifications in these structural features influence receptor selectivity, duration of action, lipophilicity, and systemic adverse effects. Such structural modifications have led to the development of short-acting and long-acting anticholinergic bronchodilators with improved therapeutic efficacy and safety.

General SAR of Anticholinergic Bronchodilators

1. Structurally derived from atropine.
2. A quaternary ammonium group limits absorption across biological membranes and prevents CNS penetration.
3. Ester linkage contributes to antimuscarinic activity.
4. Bulky hydrophobic substituents increase selectivity for bronchial muscarinic receptors.
5. Blockade of M₃ receptors inhibits vagal-mediated bronchoconstriction and produces bronchodilation.
6. Quaternary ammonium compounds reduce systemic adverse effects because of poor lipid solubility.
7. Thiophene or other lipophilic aromatic rings increase muscarinic receptor affinity and potency.
8. Slow receptor dissociation prolongs the duration of bronchodilator action.
9. Increased receptor selectivity for M₃ receptors improves airway selectivity and reduces cardiac adverse effects.
10. Increased lipophilicity contributes to prolonged retention in bronchial tissues and longer duration of action.

The SAR of anticholinergic bronchodilators demonstrates that structural features such as quaternary ammonium groups, ester linkages, and lipophilic aromatic rings are essential for antimuscarinic activity and bronchodilation. Modifications that enhance receptor selectivity and prolong receptor binding have resulted in effective short-acting and long-acting bronchodilators with improved therapeutic efficacy and reduced systemic adverse effects in asthma and COPD management.

4. Structure–Activity Relationship (SAR) of First- and Second-Generation Antihistamines

Antihistamines are drugs that block the action of histamine at H₁ receptors and are widely used in the treatment of allergic disorders such as allergic rhinitis, urticaria, and asthma-associated allergies. These agents mainly act by competitively inhibiting histamine-mediated responses, including vasodilation, bronchoconstriction, and increased vascular permeability. Structurally, most H₁-antihistamines contain two aromatic rings, a spacer chain, and a terminal tertiary amine that are essential for antihistaminic activity. Structure–Activity Relationship (SAR) studies show that modifications in aromatic substitution, lipophilicity, polarity, and stereochemistry influence receptor selectivity, potency, duration of action, and central nervous system (CNS) effects such as sedation [9]. These structural modifications have led to the development of first-generation sedating antihistamines and second-generation non-sedating antihistamines with improved safety and therapeutic efficacy.

General SAR of Antihistamines

1. Two aromatic rings are essential for H₁ receptor binding.
2. A spacer chain of 2–3 carbon atoms connects the aromatic rings to the terminal amine.
3. A tertiary amine is important for antihistaminic activity.
4. Increased lipophilicity enhances CNS penetration and sedation.
5. Polar groups reduce blood–brain barrier penetration and decrease drowsiness.
6. Carboxyl groups increase polarity and reduce CNS adverse effects.
7. Second-generation antihistamines possess greater peripheral selectivity and minimal sedation.
8. First-generation antihistamines are more lipophilic and readily cross the blood–brain barrier, producing sedation.
9. Ether linkages and hydrophobic aromatic rings contribute to antihistaminic potency.
10. Stereochemical modifications, such as active enantiomers, improve receptor selectivity and potency.

The SAR of antihistamines demonstrates that structural features such as aromatic rings, spacer chains, and tertiary amines are essential for H₁-receptor antagonistic activity. Modifications that increase lipophilicity enhance CNS penetration and sedation, whereas the introduction of polar groups reduces blood–brain barrier penetration and minimizes drowsiness. Structural optimization has led to the development of first-generation and second-generation antihistamines with improved receptor selectivity, therapeutic efficacy, longer duration of action, and reduced adverse effects in the management of allergic disorders.

5. Structure–Activity Relationship (SAR) of Second-Generation Antihistamines for Allergic Rhinitis

Second-generation antihistamines used in allergic rhinitis act by selectively blocking peripheral H₁ receptors and reducing histamine-mediated allergic symptoms such as sneezing, rhinorrhea, and nasal itching. These agents are structurally modified to minimize penetration across the blood–brain barrier, thereby reducing sedation and other CNS adverse effects [10]. SAR studies indicate that increased polarity, reduced lipophilicity, and specific aromatic substitutions improve receptor selectivity, duration of action, and safety profiles. Such structural optimization has resulted in highly selective, long-acting, and non-sedating antihistamines with improved therapeutic efficacy in allergic rhinitis and related allergic disorders.

General SAR of Antihistamines

1. Two aromatic rings are essential for H₁ receptor binding.
2. A spacer chain links the aromatic rings to the terminal amine.
3. Tertiary amines are important for antihistaminic activity.
4. Increased lipophilicity enhances CNS penetration and sedation.
5. Polar functional groups reduce blood–brain barrier penetration and decrease drowsiness.
6. Tricyclic structures improve receptor selectivity and duration of action.
7. Second-generation antihistamines possess greater peripheral selectivity with minimal CNS effects.
8. Structural modifications improve potency, safety, and therapeutic efficacy in allergic rhinitis.

The SAR of antihistamines shows that aromatic rings, tertiary amines, and structural modifications strongly influence H₁-receptor selectivity, potency, and CNS effects. The introduction of polar groups and reduced lipophilicity has resulted in second-generation antihistamines with minimal sedation and improved safety profiles. These structural advances have enhanced the therapeutic management of allergic rhinitis and related

6. Structure–Activity Relationship (SAR) of Nasal Decongestants

Nasal decongestants are sympathomimetic agents used to relieve nasal congestion associated with allergic rhinitis, sinusitis, and upper respiratory tract infections. These drugs mainly act by stimulating α-adrenergic receptors in nasal blood vessels, causing vasoconstriction and reduction of mucosal edema. Structurally, most nasal decongestants contain aromatic or imidazoline rings with side-chain substitutions that influence receptor selectivity, potency, and duration of action. Structure–Activity Relationship (SAR) studies show that modifications in lipophilicity, ring structure, and substituents significantly affect α-adrenergic activity and systemic adverse effects. These structural modifications have led to the development of effective topical decongestants with prolonged duration and reduced systemic toxicity.

General SAR of Nasal Decongestants

1. Imidazoline or phenyl ethanolamine structures are important for α-adrenergic activity.
2. Aromatic ring substitutions influence receptor selectivity and potency.
3. Imidazoline rings provide prolonged α-adrenergic action and longer duration of effect.
4. Hydroxyl substitutions improve receptor binding and vasoconstrictor activity.
5. Increased lipophilicity prolongs local action in nasal tissues.
6. Tertiary butyl substitution enhances receptor selectivity and prolongs duration of action.
7. Xylene (dimethyl-substituted aromatic) groups increase lipophilicity and improve local decongestant activity.
8. α-Adrenergic receptor stimulation causes vasoconstriction and reduces nasal mucosal edema.
9. Topical formulations reduce systemic adverse effects compared with oral decongestants.

The SAR of nasal decongestants demonstrates that imidazoline rings, aromatic substitutions, tertiary butyl groups, and lipophilic xylene moieties are important for α-adrenergic activity and prolonged vasoconstriction. Structural modifications improve receptor selectivity, duration of action, and local therapeutic efficacy while minimizing systemic adverse effects. These developments have resulted in effective topical decongestants for the management of nasal congestion.

Conclusion

Structure–Activity Relationship (SAR) studies have significantly contributed to the development and optimization of anti-asthmatic drugs. Structural modifications in corticosteroids, β₂-adrenergic agonists, anticholinergic bronchodilators, antihistamines, and nasal decongestants strongly influence receptor selectivity, potency, lipophilicity, duration of action, pulmonary selectivity, and safety profiles. Features such as halogen substitution, esterification, aromatic ring modifications, quaternary ammonium groups, tertiary amines, and lipophilic side chains enhance therapeutic efficacy while minimizing systemic adverse effects. The development of inhaled corticosteroids with improved pulmonary selectivity, long-acting bronchodilators with prolonged receptor binding, and second-generation antihistamines with minimal CNS penetration demonstrates the importance of SAR in modern medicinal chemistry. Understanding these relationships has enabled the design of safer, more effective, and patient-friendly anti-asthmatic therapies for asthma, COPD, allergic rhinitis, and related respiratory disorders.

References

1. Barnes PJ. Inhaled corticosteroids. Pharmaceutical Research. 1998;15(3):343–349.
2. Johnson M. Molecular mechanisms of β₂-adrenergic receptor function, response, and regulation. Journal of Allergy and Clinical Immunology. 2006;117(1):18–24.
3. Lipworth BJ. Pharmacokinetics of inhaled drugs. British Journal of Clinical Pharmacology. 1996;42(6):697–705.
4. Barnes PJ. The pharmacological properties of tiotropium. Chest. 2000;117(2 Suppl):63S–66S.
5. Holgate ST, Church MK. Antihistamines in allergic disease. Clinical and Experimental Allergy. 1991;21(Suppl 1):1–13.
6. Simons FE. Advances in H1-antihistamines. New England Journal of Medicine. 2004;351(21):2203–2217.
7. Gross NJ. Anticholinergic agents in asthma and COPD. European Journal of Pharmacology. 2006;533(1–3):36–39.
8. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. Journal of Allergy and Clinical Immunology. 2001;108(5 Suppl): S147–S334.
9. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in children and adults. European Respiratory Journal. 2004;24(1):40–47.
10. Matera MG, Cazzola M. Pharmacological approaches to bronchodilator therapy. Current Opinion in Pharmacology. 2007;7(3):249–257.